Who has already signed up?
ESMO gratefully acknowledges the valuable contribution the following organisations have made to the Immuno-Oncology Congress 2018. (As of September 2018):
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. We are focused on helping patients in disease areas including oncology, cardiovascular, immunoscience and fibrosis. Each day, our employees work together for patients – it drives everything we do.
- Booth: 3
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
- Booth: 7
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Merck Pfizer Alliance
Immuno-oncology is a top priority for Merck and Pfizer. The alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an anti-PD-L1 antibody initially discovered and developed by Merck. The alliance will jointly develop and commercialize avelumab and is striving to find new ways to treat cancer.
- Booth: 2
As an innovator in reagents and tools, Abcam’s purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.
- Booth: 10
Biocytogen was founded in 2009 and headquartered in Beijing, with two other affiliates in US/China. Our expertise includes generating customized gene-targeted animal models, supplying Immuno-Oncology mouse models, and performing preclinical pharmacological/pharmadynamics studies. Recently, Biocytogen has developed and validated a series of single/double humanized immune checkpoint mouse models, which are powerful tools for R&D of I-O antibodies and combinational therapies.
- Booth: 4
Fluidigm is committed to empowering the cancer immunotherapy community with research tools to interrogate the tumor microenvironment with unprecedented resolution. Whether you seek to target new biomarkers or to optimize the effectiveness of checkpoint inhibitors, CAR T cells or cancer vaccines, Fluidigm can help you reach your next research breakthrough.
- Booth: 6
For more than fifty years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer.
NeoGenomics specializes in cancer genetics testing and information services with the most comprehensive oncology-focused testing menus globally to diagnose and treat cancer. NeoGenomics operates CLIA certified laboratories serving the needs of pathologists, oncologists, academic centers, hospital systems, Pharma, and managed care organizations. Visit our website to learn more about our global locations.
- Booth: 11
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. Our Microsatillite Instability Analysis System (MSI) has been adopted as a global gold standard for characterizing tumour tissue for MSI/dMMR status, with over 120 peer-reviewed publications. The company’s 4,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification.
- Booth: 1
Seattle Genetics, an emerging multi-product, global biotechnology company, develops and commercialises transformative cancer-targeting therapies. Our lead product ADCETRIS® (brentuximab vedotin) is marketed in over 70 countries worldwide*. Seattle Genetics has a robust product pipeline designed to address significant unmet needs. Seattle Genetics is headquartered in the US, with European and International operations located in Switzerland.
- Booth: 9
*collaboration with Takeda Pharmaceutical Company Limited